Dermata reports positive Tome skincare study results
Dermata Therapeutics reported on October 15, 2026, that its once-weekly Tome Foundational Treatment produced positive topline results in an open-label cosmetic study of 31 participants. More than 71% of participants were judged to have overall skin improvement after one treatment, while 93% said the product was comparable to a professional in-office procedure and 90% reported more noticeable results than with other products. The treatment was available for purchase through Dermata's Tome website, and no treatment-related adverse events were reported.
Why it matters
The results provide Dermata with clinical data to support the commercial launch of Tome, which is now available through one-time and subscription purchase options. The materials do not report sales figures, so the study does not establish commercial traction.
Key facts
- 1The study enrolled 31 participants who applied Tome once weekly for four weeks. finanznachrichten.de
- 2More than 71% of participants were graded as having overall skin improvement after one treatment. finanznachrichten.de
- 393% of participants agreed Tome was comparable to a professional in-office procedure, and 90% agreed it produced more noticeable results than other products. investing.com
- 4No treatment-related adverse events were reported, and the product was described as well tolerated. finanznachrichten.de
- 5Tome Foundational Treatment was available through a one-time purchase of four weekly treatments or a discounted subscription program. finanznachrichten.de
- 6Dermata's shares were reported at $0.9602, up 44.75%, on volume of over 137 Million shares in the Investorideas.com report. investorideas.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.